Frontiers in Pharmacology (Apr 2021)

P2X7 Receptor–Mediated Inflammation in Cardiovascular Disease

  • Junteng Zhou,
  • Zhichao Zhou,
  • Xiaojing Liu,
  • Xiaojing Liu,
  • Hai-Yan Yin,
  • Hai-Yan Yin,
  • Yong Tang,
  • Yong Tang,
  • Xin Cao,
  • Xin Cao

DOI
https://doi.org/10.3389/fphar.2021.654425
Journal volume & issue
Vol. 12

Abstract

Read online

Purinergic P2X7 receptor, a nonselective cation channel, is highly expressed in immune cells as well as cardiac smooth muscle cells and endothelial cells. Its activation exhibits to mediate nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome activation, resulting in the release of interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), and pyroptosis, thus triggering inflammatory response. These pathological mechanisms lead to the deterioration of various cardiovascular diseases, including atherosclerosis, arrhythmia, myocardial infarction, pulmonary vascular remodeling, and cardiac fibrosis. All these worsening cardiac phenotypes are proven to be attenuated after the P2X7 receptor inhibition in experimental studies. The present review aimed to summarize key aspects of P2X7 receptor–mediated inflammation and pyroptosis in cardiovascular diseases. The main focus is on the evidence addressing the involvement of the P2X7 receptor in the inflammatory responses to the occurrence and development of cardiovascular disease and therapeutic interventions.

Keywords